[Short-term effect of navelbine on non-small cell lung cancer in 48 cases].
To evaluate effect of navelbine on non-small cell lung cancer (NSCLC). Forty eight cases of cytologically and pathologically confirmed advanced NSCLC were treated with combined chemotherapy including navelbine as the cardinal drug from May, 1995 to January, 1988. They were randomly divided into two groups. One group of 20 cases was treated with NP regimen (NVB + PDD); the other group of 28 cases was treated with NI regimen (NVB + IFO). All patients received no previous treatment. There was no complete response in patients treated with either regimen. Partial response was observed in 8 of 20 NP-treated patients(40.0%) and in 12 of 28 NI-treated patients (42.8%). There was no statistical difference in response rate between these 2 groups of NSCLC patients. However, in both groups of patients, the therapeutic effect was better in adenocarcinoma than in sequamous-cell carcinoma patients. NP regimen seemed effective in the control of bone metastases and pains. Side effects were mainly myelo-suppression and digestive tract reaction. Combined chemotherapy including NVB is worthy of use in the treatment of advanced NSCLC especially for those with bone metastasis.